

November 5, 2021

To the press and whom it may concern,

Company name: CMIC HOLDINGS Co., Ltd.

Representative: Kazuo Nakamura, Representative Director and CEO

(TSE 1<sup>st</sup> Section Code No. 2309)

Inquiries: Wataru Mochizuki, Corporate Director and CFO

(Phone: +81-3-6779-8000)

## Announcement of New Mid-term Management Plan

CMIC HOLDINGS Co., Ltd. hereby announces its formulation of Mid-term management Plan for the three-year period from the fiscal year ending September 2022 to the fiscal year ending September 2025.

### Notes

#### 1. Basic Policy

##### ■ **Transitioning from Pharmaceutical Value Creator to Personal Health Value Creator**

Using our unique PVC (Pharmaceutical Value Creator) model that fully supports the value chain of pharmaceutical companies as the foundation for sustainable growth, CMIC will aim at transitioning it to PHVC (Personal Health Value Creator) model.

#### 2. Focus Activities

##### ■ Evolution of healthcare business

- > Creation of new healthcare business to respond to health values of diverse individuals
- > Disease total care initiatives that cover prevention, diagnosis, treatment, and prognosis
- > Providing support by integrating talents and technologies such as harmo

##### ■ Comprehensive support for disease prevention, treatment R&D, and marketing

- > Maximizing the speed of market access
- > Promotion of digital transformation and drug development using the new drug discovery platform
- > Enhancing value proposition for drug discovery ventures with no presence in Japan

##### ■ Contribution to sustainable society through services with high social benefits

- > Training “healthcare professionals” who can contribute to maintain medical care system
- > Corporate activities with environmental protection and occupational health and safety

### 3. Quantitative Targets

■ Major consolidated performance indicators for the fiscal year ending September 2025 are as follows:

|                       | Targets      | Growth Rate |
|-----------------------|--------------|-------------|
| Net sales             | ¥100 billion | 3.9%        |
| Operating income      | ¥7 billion   | 9.2%        |
| Operating profit rate | 7.0%         |             |
| ROE                   | ≥10%         |             |

\* Starting point for the growth rate calculation is the fiscal year ended September 2021.